REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Enzyme Or Coenzyme Containing > Hydrolases (3. ) (e.g., Urease, Lipase, Asparaginase, Muramidase, Etc.) > Acting On Peptide Bonds (3.4) (e.g., Urokinease, Etc.) Acting On Peptide Bonds (3.4) (e.g., Urokinease, Etc.)Acting On Peptide Bonds (3.4) (e.g., Urokinease, Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/16/07 - 20070190042 - Composition for collecting and preserving placental stem cells and methods of using the composition The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ ... 07/26/07 - 20070172471 - Method for identifying an anti- streptococcal agent and its use for treating streptococcal infections A method for identifying an anti-streptococcal agent, comprises: (a) providing, as a first component, an isolated streptococcal M protein or a functional variant thereof; (b) providing, as a second component, isolated fibrinogen or a functional variant thereof; (b) providing, as a third component, an isolated β2 integrin or a functional ... 07/19/07 - 20070166297 - Human analogs of murine deubiquitinating protease The present invention is directed to human analogs of murine hematopoetic-specific, cytokine-inducible deubiquinating proteases (“DUBs”) clustered on chromosomes 4 and 8 and their respective regulatory regions. The nucleotides or proteins encoded thereby my be used in assays to identify inhibitors of human DUBs. ... 07/12/07 - 20070160594 - Method of diagnosing and treating cartilaginous disorders The present invention is directed to novel polypeptides having sequence similarity to human inter-alpha-trypsin inhibitor and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide ... 06/21/07 - 20070141042 - Methods for the treatment and prevention of diseases of biological conduits Methods are described for dilating biological conduits by removing elastin and remodeling collagens in the wall of the conduit. Methods include the use of agents that increase the release of endogenous elastase and collagenase in the wall of the conduit, either by cells that are normally present in the wall ... 06/14/07 - 20070134230 - Method for prolonging activity of autodegradable enzymes A method for prolonging the activity of an autodegradable enzyme comprises storing the enzyme after manufacture at a pH less than about 5, and reconstituting the acidified enzyme substantially immediately before use with a buffer having a pH in the range from about 6.5 to about 11, wherein the pH ... 06/14/07 - 20070134229 - Non-native constitutively active osteopontin Non-native constitutively phosphorylated forms of osteopontin are disclosed. Such osteopontin forms can be obtained, for example, using an expression vector comprising an isolated nucleic acid that encodes an osteopontin peptide, operably linked to a promoter wherein the osteopontin peptide is either constitutively phosphorylated or is capable of being constitutively phosphorylated. ... 06/07/07 - 20070128181 - Methods of preventing morbidity and mortality by perioperative administration of a blood clotting inhibitor The present invention provides methods of using a blood clotting inhibitor to reduce post-surgical morbidity and mortality. In particular, perioperative use of a blood clotting inhibitor decreases surgical complications without significant adverse effects and is cost effective. ... 05/24/07 - 20070116699 - Nattokinase for reducing whole blood viscosity Disclosed is a method for reducing whole blood viscosity in a patient in need thereof. The method includes administering a composition that comprises nattokinase. The composition may be administered to any patient that may benefit from a reduction in blood viscosity, such as a patient having or at risk for ... 05/17/07 - 20070110739 - Wipe away pain A topical composition for treating stings and insect bites effectively significantly reducing pain and/or eliminating it (wiping away pain, or WAP) is disclosed comprising a stabilized proteonaise, antibacterial/anti-microbial, a cooling agent, an anti-inflammatory agent, a debriding agent and an exfoliating agent. ... 05/03/07 - 20070098709 - Methods for treating and preventing diabetic retinopathy This invention provides a method for treating diabetic retinopathy in a subject afflicted therewith, comprising administering to the subject's eyes a therapeutically effective amount of an agent that modulates the binding between AGE and RAGE in the subject's eyes, wherein the agent is not soluble RAGE or a derivative thereof, ... 04/12/07 - 20070081988 - Enzyme inhibitors of pai-1 The invention provides a method for the treatment of a subject suffering from a cardiovascular disease using a therapeutically effective amount of at least one enzyme that is capable of inhibiting PAI-1 activity. The invention also provides a method of decreasing the risk of the occurrence of a cardiovascular disease ... 04/12/07 - 20070081987 - Novel peptides and compositions which modulate apoptosis The present invention is directed to novel peptides and compositions capable of modulating apoptosis in cells, and to methods of modulating apoptosis employing the novel peptides and compositions of the invention. In one aspect, the invention is directed to a novel peptide designated the “GD domain,” which is essential both ... 03/29/07 - 20070071741 - Ocl-2a3 compositions and uses thereof This invention relates to osteoclast-specific genes and proteins. Specifically, the invention relates to OCL-2A3 or Atp6v0d2, the gene encoding it and uses thereof in methods and treatment of bone disorders. ... 03/08/07 - 20070053898 - Method for reducing allergencity in indoor spaces According to this invention, allergenicity in an indoor space is reduced by denaturing allergens in allergen reservoirs that are capable of producing respiratory or skin reactions and physically removing the allergens from the allergen reservoirs in the indoor space. The allergen reservoirs may also be treated with pesticides and fungicides/fungistats ... 02/22/07 - 20070041960 - Apparatus and methods for enzymatic debridement of skin lesions An apparatus for debridement of devitalized tissue in skin lesions, that includes a plurality of height- and angle-adjustable inlet tubes and at least one outlet tube and a member that forms an occlusive seal around a skin lesion. The plurality of inlet tubes is adapted for directing a continuous stream ... 02/08/07 - 20070031399 - Use of proline specific endoproteases to hydrolyse peptides and proteins The present invention relates to a process for the proteolytic hydrolysis of a peptide or a polypeptide, said peptide or polypeptide comprising 4 to 40, preferably 5 to 35, amino acid residues and said peptide or polypeptide is not hydrolysable by subtilisin whereby said peptide or polypeptide is hydrolysed by ... 02/08/07 - 20070031398 - One of several enzyme-containing compounds, dietetic food products and drugs produced from and the use therefor for medical purpose The invention relates to one or several enzyme-containing compounds, i.e. to one or several hydrolyses and to one or several antioxidants which are selected from ubiquinones, carotinoides and antioxidative vitamins. The inventive compounds are used in the form of components for producing food products or drugs which are used, inter ... 02/01/07 - 20070025978 - Bactiophage lysins for enterococcus faecalis, enterococcus faecium and other bacteria The present disclosure relates to bacteriophage lysins useful for the reduction of certain bacterial populations, including methods and compositions for the treatment of various bacterial infections. For example, bacteriophage lysins were isolated and shown to effectively kill various bacteria, including both E. faecalis and E. faecium (including vancomycin resistant strains), ... 01/25/07 - 20070020254 - Methods and compositions for treatment of inflammatory disease Compositions useful for treating inflammatory diseases including arthritis are disclosed which comprise cetyl myristoleate compounds or related compounds and at least one compound useful for treatment of inflammatory disease, such as tetracycline compounds, Cox-2 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, local anaesthetics, chelating agents, matrix metalloprotease inhibitors, inhibitors of inflammatory ... 01/18/07 - 20070014779 - Plasminogen activator variant formulations A solution is provided comprising about 0.01-0.05 mg/mL of tenecteplase in sterile water for injection or bacteriostatic water for injection and normal saline. Such solution is useful for delivery from a catheter and for treating a thrombotic disorder by exposing fibrin-rich fluid from the disorder to an effective amount thereof, ... 01/11/07 - 20070009505 - Composition and system for wound decontamination The present disclosure is directed to a cleansing solution and system for administering the cleansing solution to decontaminate a wound surface. A method and kit for decontaminating a wound surface is also provided. ... 12/14/06 - 20060280731 - Novel substrate for rpn11 enzymatic activity The present application provides peptides that serve as substrates for proteasome enzymatic activity, e.g., the enzymatic activity of Rpn11, a metalloprotease of the 19S regulatory particle. The present application also provides methods and compositions employing the peptide substrates. ... 11/30/06 - 20060269539 - Asp2 ASP2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ASP2 polypeptides and polynucleotides in the design of protocols for the treatment of Alzheimer's Disease, cancer, and prohormone processing, among others, and diagnostic assays for such conditions. ... 11/30/06 - 20060269538 - Serine proteases with altered sensitivity to activity-modulating substances The present invention provides variants of serine proteases of the S1 class with altered sensitivity to one or more activity-modulating substances. A method for the generation of such proteases is disclosed, comprising the provision of a protease library encoding polynucleotide sequences, expression of the enzymes, screening of the library in ... 11/23/06 - 20060263346 - Combined pharmaceutical preparations for the treatment of cancer, containing glutaminase and antineoplastic anthracyclines or platinum compounds The invention concerns combined pharmaceutical preparations which inhibit abnormal growth of tumor cells. The combined preparations comprise as active substances compounds having glutaminase activity in combination with certain antineoplastic agents. The invention concerns in particular combined preparations of compounds having glutaminase activity and cytostatic compounds. ... 11/16/06 - 20060257390 - Catheter composition and uses thereof A composition useful for removal of fibrin-bound blood clots from a catheter comprises water, a fibrinolytically effective amount of a plasminogen activator, and a preservatively effective amount of a bacteriostatic organic alcohol. The composition does not comprise a chelating agent. ... 11/16/06 - 20060257389 - Diagnosis of blood clots using fibrin-binding proteins bound with contrast agents This invention describes how to modify a fibrin-binding protein, such as tPA, with a contrast agent, such as iodine. This substance could then be given to a patient suspected of having a blood clot by an intravenous route, and then detected by a radiographic study at a short pre-determined time ... 11/02/06 - 20060246051 - Polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, bgs42 The present invention provides novel polynucleotides encoding BGS-42 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-42 polypeptides to the diagnosis, treatment, and/or prevention ... 11/02/06 - 20060246050 - Catheter composition and uses thereof A composition useful for removal of fibrin-bound blood clots from a catheter comprises water, a fibrinolytically effective amount of a plasminogen activator, and a preservatively effective amount of a bacteriostatic organic alcohol. The composition does not comprise a chelating agent. ... 10/26/06 - 20060239993 - Drug containing angiotensin convertase The medicine containing angiotensin-converting enzyme or its peptidase-inactivated mutants that specifically releasing GPI-anchored proteins from the cell surface, for preventing or curing diseases, such as prion-related diseases, inflammatory diseases, bacterial infectious diseases and male infertility due to sperm-egg binding insufficiency. ... 10/05/06 - 20060222637 - Proliferation of muc1 expressing cells The present application discloses a method for stimulating or enhancing proliferation of a population of cells by activating MUC1 receptor on the cells. ... 09/21/06 - 20060210549 - Controlled release liposomes and methods of use The present invention provides liposomes that include a trigger polypeptide, a lipid layer, and a compartment surrounded by the lipid layer and methods of using the liposomes. ... 09/21/06 - 20060210548 - Method for reducing obstructive hydrocephalus A process for reducing cerebrospinal fluid flow obstruction includes the administration of a therapeutic dose of a clot-reducing agent to a subject having preconditions or obstructive hydrocephalus symptoms. The dose is maintained within the subject for a period of time sufficient to reduce cerebrospinal fluid flow obstruction. The clot-reducing agent ... 09/14/06 - 20060204489 - Protein c derivatives Novel human protein C derivatives are described. These derivatives have increased anti-coagulation activity compared to wild-type protein C and retain the biological activity of the wild-type human protein C. These derivatives will require either less frequent administration and/or smaller dosage than wild-type human protein C in the treatment of acute ... 09/14/06 - 20060204488 - Methods for treating adhesive capsulitis The invention relates to the discovery that collagenase injections are effective in lyse the collagenous adhesions in the shoulder and treat the disorder, adhesive capsulitis. As such, the invention relates to methods of treating or preventing adhesive capsulitis, or frozen shoulder, in a patient in need of such treatment comprising ... 09/07/06 - 20060198835 - Nucleic acid molecules encoding osteogenic proteins Disclosed are 1) osteogenic devices comprising a matrix containing osteogenic protein and methods of inducing endochondral bone growth in mammals using the devices; 2) amino acid sequence data, amino acid composition, solubility properties, structural features, homologies and various other data characterizing osteogenic proteins, 3) methods of producing osteogenic proteins using ... 09/07/06 - 20060198834 - Chaperonin 10 immunosuppression The invention is directed to the use of cpn10 in transplantation and particularly to treatment and/or prevention of graft versus host disease. The invention provides a method of administration of cpn10 to a donor and/or recipient animal or cells, tissues or organs derived from the donor, although in a particularly ... 07/13/06 - 20060153830 - Proteases from carica having mitogenic activity and their methods of use Proteases having mitogenic activity isolated from the genus Carica are provided. In particular the proteases are cysteine proteases isolated from Carica candamarcensis. In addition, the recombinant forms of the protease, including fragments and mutants with substantial homology are provided. Also provided are pharmaceutical compositions useful for treating wounds that include ... 07/13/06 - 20060153829 - Stable formulations of purified proteins This application provides methods of improving protein replacement therapy by combining protein replacement therapy with active site-specific chaperones (ASSC) to increase the stability and efficiency of the protein being administered. The application further provides stable compositions comprising the purified protein and an ASSC, and methods of treatment by administering the ... 07/13/06 - 20060153828 - Method of reducing the viscosity of mucus Disclosed is a pO157 plasmid-specified polypeptide found in E. coli EDL933 and other E. coli that binds to and cleaves C1-esterase inhibitor, and antibodies specific for the polypeptide. Also disclosed are methods employing the polypeptide for diagnosing enterohemorrhagic E. coli infection, identifying potential inhibitors of its activity, and reducing viscosity ... 07/13/06 - 20060153827 - Chimeric protein A chimeric protein is disclosed for promoting repair and regeneration of neurons damaged by disease or physical injury wherein the chimeric protein is a combination of a first polypeptide possessing matrix modification activity and a second polypeptide possessing regenerating activity for neural cells. ... 07/06/06 - 20060147443 - Synthetic biomaterials having incorporated therein bioactive factors through enzymatically degradable linkages Synthetic biomaterials containing bioactive factors or modified bioactive factors that are covalently bound to the synthetic precursor components and/or biomaterials by an enzymatically degradable linkage are described herein. Further described are methods to covalently bind bioactive factors to synthetic biomaterials by means of enzymatic catalysis, the biomaterials produced therewith and ... 06/29/06 - 20060140929 - Modified hirudin proteins and t-cell epitopes in hirudin The invention concerns hirudin and in particular modified forms of hirudin with improved properties. The improved proteins contain amino acid substitutions at specific positions. The invention provides modified hirudin with improved biological activity concomitant with reduced immunogenic potential in the protein. The improved proteins are intended for therapeutic use in ... 06/22/06 - 20060134092 - Method of degrading hardly degradable protein Disclosed is an agent for digesting a protein highly resistant to denaturation and degradation, comprising as an active ingredient an enzyme exhibiting an activity of digesting a protein highly resistant to denaturation and degradation and having the following properties: (a) activity and substrate specificity: hydrolyzing a peptide bond of a ... 06/01/06 - 20060115469 - Interstitial collagenase molecular motor A novel interstitial collagenase is disclosed which acts as an ATP-independent molecular motor driven by the proteolysis of substrate collagen. Also disclosed is a method of reacting interstitial collagenase with a collagen fibril to encounter multiple cleavage sites without substantial dissociation of said interstitial collagenase and thereby act as a ... 05/25/06 - 20060110380 - Compositions for inhibiting thrombin-induced coagulation and methods of use A method of achieving safe and effective treatment or prevention of potentially harmful blood clots, or in inhibiting the coagulation of blood when so desired such as during a wide array of disease conditions including stroke, myocardial infarction, sickle-cell crisis and venous thrombosis, is provided by the administration of a ... 05/18/06 - 20060104969 - Compositions and methods for enhancing structural and functional nervous system reorganization and recovery The present invention provides methods and compositions for enhancing recovery in a subject suffering from damage to the nervous system. In particular, the invention includes a method for promoting recovery and/or reorganization in the nervous system of a subject in need of enhancement of recovery and/or reorganization of the nervous ... 04/13/06 - 20060078554 - Angiotensin peptide-carrier conjugates and uses thereof The present invention provides conjugates of peptide derivatives of the mammalian peptide hormones angiotensinogen, angiotensin I and angiotensin II, presented in a repetitive scaffold by coupling the peptide derivatives to a carrier, particularly a virus-like particle (VLP). The invention also provides methods of producing such conjugates, and immunotherapeutic uses of ... 03/02/06 - 20060045875 - Method of use of crotoxin as an anti-retroviral agent The present invention provides a composition of matter and a method of using the composition for treating and preventing of retroviral infections of mammalian cells. It includes identification of Crotalus beta-neurotoxins as capable of preventing HIV infection and replication in that cell and a retroviral composition which can be administered ... 02/16/06 - 20060034823 - Method of production and use of crotoxin as an analgesic Disclosed a pharmaceutical composition including one of crotoxin, mojavetoxin or a related toxin and a carrier for use in the treatment of chronic pain, especially to the treatment of heretofore intractable pain such as that associated with advanced cancer wherein the treatment is independent of the reduction of tumors. The ... 02/09/06 - 20060029591 - Repair of larynx, trachea, and other fibrocartilaginous tissues Provided herein are methods and devices for inducing the formation of functional replacement nonarticular cartilage tissues and ligament tissues. These methods and devices involve the use of osteogenic proteins, and are useful in repairing defects in the larynx, trachea, interarticular menisci, intervertebral discs, ear, nose, ribs and other fibrocartilaginous tissues ... 02/09/06 - 20060029590 - Administration of neutral endopeptidase to treat inflammatory bowel disease Administration of recombinant, truncated mammalian NEP or certain bacterial homologues of this protein is therapeutically effective in the treatment of inflammatory bowel disease. ... 02/09/06 - 20060029589 - Induction of heterozygous fv leiden carrier status to reduce mortality in sepsis and to prevent organ damage caused by inflammation and/or ischemia-reperfusion injury A method of treating a disease is disclosed. In one embodiment, the method comprises administering to a patient an effective amount of factor V protein or fragment of factor V protein, wherein the amount of protein is sufficient to alleviate or prevent disease symptoms and wherein the protein is resistant ... 01/05/06 - 20060002917 - Effect of prolyl endopeptidase on digestive-resistant gliadin peptides in vivo Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten. ... 01/05/06 - 20060002916 - Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1 MT-SP1 mutein proteases with altered specificity for the target molecules they cleave can be used to treat human diseases, such as cancer. Cleaving VEGF or VEGFR at certain substrate sequences with wild-type and mutein MT-SP1 proteases can be used to treat pathologies associated with angiogenesis. ... 12/29/05 - 20050287135 - Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins An injectable or implantable rod-shaped formulation is disclosed for delivery of osteogenic proteins. The formulation comprises hyaluronic acid derivatives and osteogenic proteins, and optional excipients and active ingredients such as a bone resorption inhibitor. Methods of making injectable rod-shaped pharmaceutical compositions and methods of using the osteogenic compositions to treat ... 11/17/05 - 20050255095 - Destruction of prions using vibrolysin or variants thereof The present invention provides a method of reducing the activity of prions using vibriolysin or variants thereof. Vibriolysin-containing solutions are used to sanitize prion-contaminated facilities and instruments and decontaminate food products and biological tissues. The present invention provides a method of treating prion-related disease in animals and humans, comprising the ... 11/10/05 - 20050249719 - Enzyme treatment of foodstuffs for celiac sprue Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten. ... 10/20/05 - 20050232913 - Short chain neurotoxin from sea snake-lapemis hardwickii and genes encoding the neurotoxin In this invention, three genes encoding short chain neurotoxin are obtained by sea snake—Lapemis hardwickii venom gland cDNA library construction and DNA sequencing, named sn12, sn36, and sn160, respenctively. The three genes are modified and amplified by PCR method, then cloned into expression vector PETTRX. The three neurotoxin genes are ... 10/06/05 - 20050220781 - Ifix, a novel hin-200 protein, for cancer therapy The present invention regards IFIX proteins, polypeptides, peptides, and the polynucleotides that encode them. In particular embodiments, the IFIX proteins, polypeptides, and/or peptides comprise tumor suppressive, anti-cell proliferative pro-apoptotic and/or cell cycle arrest-inducing activities. In more particular embodiments, these forms are useful for cancer therapy, particularly when administered in combination ... 10/06/05 - 20050220780 - Pharmaceutical composition having thrombolytic anti-inflammatory and cytoprotective properties A pharmaceutical composition having thrombolytic, anti-inflammatory and cytoprotective properties is described. The composition contains active proteases attached to a gel or to a mixture of a gel with a water-soluble polymer, said attachment being achieved with the help of radiation, preferably with the help of gamma-radiation or a flow of ... 09/22/05 - 20050208038 - Phage-associated lytic enzymes for treatment of streptococcus pneumoniae and related conditions The present disclosure relates to methods, compositions and articles of manufacture useful for the treatment of Streptococcus pneumonia bacteria and spores, and related conditions. The disclosure further relates to methods and compositions for the identification of a phage associated lytic enzyme to rapidly kill Streptococcus pneumoniae and other bacteria. Related ... 07/21/05 - 20050158300 - Compositions and methods for modulating muscle cell and tissue contractility The present invention relates to compositions and methods comprising one or more domains of urokinase-type plasminogen activator (UPA) in an amount effective to modulate one or more of the contractility and angiogenic activity of a mammalian muscle or endothelial cell or tissue for use in the treatment of a disease ... 07/21/05 - 20050158299 - Non-pancreatic proteases for controlling plasma cholecystokinin (cck) concentration and for treating pain This invention relates to methods for maintaining the basal level or reducing the level of cholecystokinin (CCK) in blood plasma of a mammal. Additionally, the invention provides methods for treating pain in a mammal and more particularly, methods for treating abdominal pain in a mammal. The methods include administering to ... 07/21/05 - 20050158298 - Novel fungal proteins and nucleic acids encoding same Disclosed herein are fungal nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The novel leucine aminopeptidase (LAP) and other amino- and carboxypeptidases polypeptides, referred to herein ... 07/14/05 - 20050152888 - Targeted polypeptide degradation This invention pertains to compositions, methods, cells and organisms useful for selectively localizing polypeptides to the proteasome for degradation. Therapeutic methods and pharmaceutical compositions for treating disorders associated with the expression and/or activity of a polypeptide by targeting these polypeptides for degradation, as well as methods for targeting therapeutic polypeptides ... 07/07/05 - 20050147599 - Medical implants and fibrosis-inducing agents Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue. ... 06/30/05 - 20050142128 - Treatment for diseases of the eye inner ear and central nervous system The present invention relates to 5,6-dihydroxyindole (DHI), 5,6-dihydroxyindole-2-carboxylic acid (DHICA) and/or 5-S-cysteinyldopa (CD) as medicaments, as well as their use, and the use of tyrosinase for the preparation of a medicament for prophylaxis or therapy of diseases induced by oxidative stress. Furthermore, the present invention relates to the use of ... 06/23/05 - 20050136045 - Identification, production and use of staphylokinase derivatives with reduced immunogenicity and/or reduced clearance Methods for the identification, production and use of staphylokinase derivatives characterized by a reduced immunogenicity after administration in patients and that can be administered by a single bolus injection. The derivatives of the invention are obtained by preparing a DNA fragment comprising at least part of the coding sequence of ... 06/02/05 - 20050118159 - Truncated lysostaphin molecule with enhanced staphylolytic activity This invention relates to the production of recombinant lysostaphin in a homogenous form through the use of recombinant DNA molecules that express homogenous lysostaphin and host cells transformed with these DNA molecules. This invention also relates to the production of truncated forms of lysostaphin. The resulting lysostaphin preparations can be ... ### FreshPatents.com Support |